Second Opinion
Is Healthcare Safe From the SaaS Bloodbath? With Omada CEO Sean Duffy and Stephanie Davis
Why It Matters
Understanding how digital health companies are insulated from the broader SaaS “bloodbath” helps investors and operators gauge risk and set realistic expectations for valuation and growth. As AI reshapes cost structures, the episode highlights why outcome‑based care models and regulatory barriers make healthcare a uniquely stable arena in a volatile tech market.
Key Takeaways
- •Healthcare tech blends software with regulated care services.
- •Outcomes, not software, drive revenue for companies like Omada.
- •SaaS downturn less threatens health tech due to resilient demand.
- •AI can boost margins but cannot replace human care components.
- •Investors misjudge health tech valuations, causing market volatility.
Pulse Analysis
The conversation opened by highlighting that digital health isn’t pure software; it’s a regulated platform‑as‑a‑service that couples technology with hands‑on care teams. Omada exemplifies this model, selling outcomes—weight loss, chronic‑disease management—rather than a license. Their NCQA accreditation, HIPAA compliance, and device supply chain illustrate why health‑tech firms operate more like providers than traditional SaaS vendors, and why outcome‑based pricing drives revenue.
When the broader SaaS market faced a valuation correction fueled by AI hype, panelists argued health tech remains comparatively insulated. Margins in pure software can soar, but health‑tech companies historically hover at lower, service‑heavy levels. The demand for doctors, hospitals, and chronic‑care programs is structurally resilient, cushioning firms like Omada from the worst of the software bloodbath. AI, while promising efficiency gains, is viewed as a margin enhancer rather than a substitute for the human touch that underpins patient outcomes.
Nevertheless, investors often misinterpret the sector, applying pure‑software multiples to businesses that still rely on extensive compliance, staffing, and long‑term contracts. This misunderstanding fuels volatility and undervalues companies with solid cash‑flow potential. Analysts suggest a shift toward value‑oriented pricing—charging for outcomes or per‑member‑per‑month services—will better align expectations. As AI matures, it will augment, not replace, the care continuum, offering a balanced growth path for digital health firms navigating both market headwinds and regulatory realities.
Episode Description
In this episode of Lifers, Christina Farr joins Omada Health CEO Sean Duffy and healthcare industry analyst Stephanie Davis to discuss whether digital health is a resilient "safe haven" or a casualty in the current public market software "blood bath". They explore how healthcare differs from traditional SaaS because it relies on "between-visit" provider care, physical touch, and rigorous regulatory compliance rather than just "vibe-coded" software, analyze recent M&A activity, such as UHS acquiring Talkspace, and discuss how AI might shift the industry toward a "creator" model while maintaining the essential "human-in-the-loop" for patient accountability. Dive into the Granola notes from this episode: https://notes.granola.ai/t/ed07ad4e-18c1-4f8c-a8c9-9e3a17cc68c3-008umkv4 —SPONSOR: GranolaGranola AI, The AI notepad for people in back-to-back meetings: https://granola.ai/lifers with code: LIFERSInterested in sponsoring the show? lifers@a16zstudios.com —LINKS:The 2028 Global Intelligence Crisis - Citrini Research: https://www.citriniresearch.com/p/2028gicChamath Article: https://x.com/chamath/status/2033385903520129161Chrissy Farr’s Website: https://www.chrissyfarr.com/ Subscribe to the Second Opinion Newsletter: https://secondopinion.media/ Chrissy’s Book: The Storyteller's Advantage: https://www.chrissyfarr.com/books Lifers with Christina Farr on YouTube: https://www.youtube.com/@LiferswithChristinaFarr —FOLLOW:Sean:https://www.linkedin.com/in/seanpduffy/https://x.com/seanduffyStephanie:https://www.linkedin.com/in/stephjdavis/Chrissy:https://www.linkedin.com/in/christinafarr/https://x.com/chrissyfarr—TIMESTAMPS:(00:00) Preview(00:24) Intro(00:47) Analyzing the SaaS market bloodbath and healthcare's unique position(02:09) Omada Health's evolution from vendor to regulated care provider(04:21) Challenging the pandemic-era trend of valuing services like software(06:09) Evaluating end-market resilience for doctors versus white-collar workers(08:17) Shifting revenue models from seat licenses to value-based outcomes(11:12) Navigating the psychological shift from growth multiples to cash flow(13:51) Perception versus reality in a nascent and misunderstood industry(15:52) Bridging the gap between technology and healthcare venture capital(18:07) Sponsor: Granola(18:46) The Talkspace acquisition as a bellwether for incumbent interest(21:42) Managing clinical and regulatory governance in the age of AI(25:02) Using LLMs to navigate complex employer benefit ecosystems(28:35) Balancing the science of models with the art of medicine(29:44) Future-proofing careers by leveraging AI tools for creative creation(34:45) Wrap
Comments
Want to join the conversation?
Loading comments...